Journal of Otology & RhinologyISSN: 2324-8785

Reach Us +1 850 754 6199

Case Report, J Otol Rhinol Vol: 2 Issue: 2

Delayed Onset of Infection Development after Polyalkylimide Treatment for HIV-Associated Lipoatrophy

Anisha R Kumar*, Macario Camacho and Robson Capasso 
Department of Otolaryngology, Stanford University School of Medicine, 801 Welch Road, Stanford, CA 94305, USA
Corresponding author : Anisha R Kumar
Department of Otolaryngology, Stanford University School of Medicine, 801 Welch Road, Stanford, CA 94305
Tel: 914 500 5680
E-mail: [email protected]
Received: February 07, 2013 Accepted: April 09, 2013 Published: April 10, 2013
Citation: Kumar AR, Camacho M, Capasso R (2013) Delayed Onset of Infection Development after Polyalkylimide Treatment for HIV-Associated Lipoatrophy. J Otol Rhinol 2:2. doi:10.4172/2324-8785.1000115

Abstract

Delayed Onset of Infection Development after Polyalkylimide Treatment for HIV-Associated Lipoatrophy

Bio-Alcamid, a polyalkylimide, is a non-reabsorbable polymeric substance and has been used in cosmetic and reconstructive surgery. The material is widely used because it is non-toxic, non-allergenic, easily injectable, and quickly removable. Polyalkylimide has been used for the cosmetic treatment of atrophy of subcutaneous tissue and HIV-associated lipoatrophy due to highly active antiretroviral therapy (HAART). In HIV-patients who received this treatment, immediate therapy within zero to six weeks proved more beneficial in reducing facial lipoatrophy compared to the delayed therapy within twelve to eighteen weeks. Furthermore, in the duration of four years after the polyalkylimide treatment is administered, patients have not experienced necrosis, nodules, or infection.

Keywords: Polyalkylimide Treatment; HIV; Lipoatrophy; Highly Active Antiretroviral Therapy

Track Your Manuscript

Share This Page

Media Partners

Associations